It is well known that only 1 to 3% of human circulating T cells expressed CD103, which implies that tumor-specific T cells need to encounter the cognate antigen within a TGF-β-rich tumor microenvironment to induce expression of the integrin and to become TRM. Here, TGFB1 is linked to neoplasm.